Solventum to Participate in the Piper Sandler Healthcare Conference
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment
Solventum Co. (NYSE: SOLV) had its price target raised by analysts at Morgan Stanley from $60.00 to $73.00. They now have an "equal weight" rating on the stock.
Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance
Solventum to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024